Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.



trial #
trial description
  • Alliance A091304
  • The purpose of this study is to test the safety of a study drug called MLN0128. MLN0128 has been studied in cancer patients. This drug has been tested in animals but this version has not yet been tested in people. This study tests different doses of the drug to see which dose is safer in people.

  • Alliance A091401
  • The purpose of this study is to test any good and bad effects of the study drugs called nivolumab and ipilimumab. Nivolumab alone or with ipilimumab could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to its present size, and to learn more about the side effects and science of the treatment. 

  • CTSU ADVL1622
  • CTSU/COG AOST 1321
  • In this study, researchers want to find out if we can improve the treatment for subjects with recurrent or refractory osteosarcoma by giving a drug called denosumab.   Denosumab has been Food and Drug Administration (FDA) approved for the treatment of adults and adolescents with mature bones who have a giant cell tumor of the bone that cannot be treated with surgery or if surgery is not possible.  The use of denosumab in adolescents and young adults for osteosarcoma that is not responding to treatment or has come back after treatment is experimental. This is the first study of denosumab in patients who have osteosarcoma. The overall goal of this study is to find out what effects, good and/or bad, denosumab has on people with recurrent or refractory osteosarcoma. Denosumab could slow tumor growth or shrink the tumor but it could also cause side effects. 

  • In this study, researchers want to find out if we can improve the treatment for subjects (people who agree to take part in this study) with intermediate and high risk Non Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) by adding an experimental drug called pazopanib to standard therapy.  In adults with certain types of NRSTS pazopanib has been shown to have anti-tumor activity and it is FDA approved for use in adults with certain diseases, including advanced soft tissue sarcoma. Pazopanib has also been used in a small study in children with cancer. Although pazopanib is experimental for use in intermediate and high risk NRSTS, it has been shown to be well tolerated in children and adults. Pazopanib is approved in adults with certain diseases but is considered investigational in children and certain adults.